HeyburnL, MoussaCE: TDP-43 in the spectrum of MND-FTLD pathologies. Mol Cell Neurosci, 2017; 83:46–54.
2.
LiachkoNF, SaxtonAD, McMillanPJ, StrovasTJ, CurreyHN, TaylorLM, et al.: The phosphatase calcineurin regulates pathological TDP-43 phosphorylation. Acta Neuropathol, 2016; 132:545–561.
3.
KumarA, SinghN: Calcineurin inhibitors improve memory loss and neuropathological changes in mouse model of dementia. Pharmacol Biochem Behav, 2017; 153:147–159.
4.
BuoniS, ZannolliR, SorrentinoL, FoisA: Betamethasone and improvement of neurological symptoms in ataxia-telangiectasia. Arch Neurol, 2006; 63:1479–1482.
5.
ZannolliR, BuoniS, BettiG, SalvucciS, PlebaniA, SoresinaA, et al.: A randomized trial of oral betamethasone to reduce ataxia symptoms in ataxia telangiectasia. Mov Disord, 2012; 27:1312–1316.
6.
BroccolettiT, Del GiudiceE, CirilloE, ViglianoI, GiardinoG, GinocchioVM, et al.: Efficacy of very-low-dose betamethasone on neurological symptoms in ataxia-telangiectasia. Eur J Neurol, 2011; 18:564–570.
7.
GiardinoG, FuscoA, RomanoR, GalloV, MaioF, EspositoT, et al.: Betamethasone therapy in ataxia telangiectasia: unraveling the rationale of this serendipitous observation on the basis of the pathogenesis. Eur J Neurol, 2013; 20:740–747.
8.
PandolfiA, FloritaM, AltomareG, PigattoP, DonatiMB, PoggiA: Increased plasma levels of platelet-derived growth factor activity in patients with progressive systemic sclerosis. Proc Soc Exp Biol Med, 1989; 191:1–4.
9.
AgacheI, RădoiM, DucaL: Platelet activation in patients with systemic scleroderma—pattern and significance. Rom J Intern Med, 2007; 45:183–191.
10.
NtelisK, GkizasV, FilippopoulouA, DavlourosP, AlexopoulosD, AndonopoulosAP, et al.: Clopidogrel treatment may associate with worsening of endothelial function and development of new digital ulcers in patients with systemic sclerosis: results from an open label, proof of concept study. BMC Musculoskelet Disord, 2016; 17:213.
11.
HirataH, OkamotoK, BereiterDA: GABA(A) receptor activation modulates corneal unit activity in rostral and caudal portions of trigeminal subnucleus caudalis. J Neurophysiol, 2003; 90:2837–2849.
12.
LichtingerA, PurcellTL, SchanzlinDJ, ChayetAS: Gabapentin for postoperative pain after photorefractive keratectomy: a prospective, randomized, double-blind, placebo-controlled trial. J Refract Surg, 2011; 27:613–617.
13.
NissmanSA, TractenbergRE, Babbar-GoelA, PasternakJF: Oral gabapentin for the treatment of postoperative pain after photorefractive keratectomy. Am J Ophthalmol, 2008; 145:623–629.
14.
AnfusoCD, OlivieriM, FidilioA, LupoG, RuscianoD, PezzinoS, et al.: Gabapentin attenuates ocular inflammation: in vitro and in vivo studies. Front Pharmacol, 2017; 8:173.
15.
JordheimLP, Ben LarbiS, FendrichO, DucrotC, BergeronE, DumontetC, et al.: Gemcitabine is active against clinical multiresistant Staphylococcus aureus strains and is synergistic with gentamicin. Int J Antimicrob Agents, 2012; 39:444–447.
16.
Doléans-JordheimA, BergeronE, BereyziatF, Ben-LarbiS, DumitrescuO, MazoyerMA, et al.: Zidovudine (AZT) has a bactericidal effect on enterobacteria and induces genetic modifications in resistant strains. Eur J Clin Microbiol Infect Dis, 2011; 30:1249–1256.
17.
MascellinoMT, IonaE, IegriF, De GregorisP, FarinelliS: In vitro activity of zidovudine alone and in combination with ciprofloxacin against Salmonella and Escherichia coli. FEMS Immunol Med Microbiol, 1993; 7:23–28.
18.
SommadossiJP, CarlisleR, SchinaziRF, ZhouZ: Uridine reverses the toxicity of 3′-azido-3′-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity. Antimicrob Agents Chemother, 1988; 32:997–1001.
19.
ShepherdAJ, BarrP, LewinCS: The effect of thymidine on the antibacterial and antiviral activity of zidovudine. J Pharm Pharmacol, 1992; 44:704–706.
GarstkiewiczM, StrittmatterGE, GrossiS, SandJ, FeniniG, WernerS, et al.: Opposing effects of Nrf2 and Nrf2-activating compounds on the NLRP3 inflammasome independent of Nrf2-mediated gene expression. Eur J Immunol, 2017; 47:806–817.
22.
LaiK, KillingsworthMC, LeeCS: Gene of the month: PIK3CA. J Clin Pathol, 2015; 68:253–257.
23.
AndersonS, BrooksSS: An extremely rare disorder of somatic mosaicism: CLOVES syndrome. Adv Neonatal Care, 2016; 16:347–359.
24.
LimayeN, KangasJ, MendolaA, GodfraindC, SchlögelMJ, HelaersR, et al.: Somatic activating PIK3CA mutations cause venous malformation. Am J Hum Genet, 2015; 97:914–921.
CarolH, GorlickR, KolbEA, MortonCL, ManeshDM, KeirST, et al.: Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer, 2014; 61:245–252.
27.
ChildF, Ortiz-RomeroPL, AlvarezR, BagotM, StadlerR, WeichenthalM, et al.: Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome. Br J Dermatol, 2016; 175:80–88.
28.
ChuaMJ, ArnoldMS, XuW, LancelotJ, LamotteS, SpäthGF, et al.: Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth. Int J Parasitol Drugs Drug Resist, 2017; 7:42–50.
29.
YamashitaY, UeyamaT, NishiT, YamamotoY, KawakoshiA, SunamiS, et al.: Nrf2-inducing anti-oxidation stress response in the rat liver—new beneficial effect of lansoprazole. PLoS One, 2014; 9:e97419.
30.
CronicanAA, FitzNF, PhamT, FoggA, KiferB, KoldamovaR, et al.: Proton pump inhibitor lansoprazole is a nuclear liver X receptor agonist. Biochem Pharmacol, 2010; 79:1310–1316.
31.
TsaiCF, ChenMH, WangYP, ChuCJ, HuangYH, LinHC, et al.: Proton pump inhibitors increase risk for hepatic encephalopathy in patients with cirrhosis in a population study. Gastroenterology, 2017; 152:134–141.
32.
LiL, ZhangS, ZhangX, LiT, TangY, LiuH, et al.: Autophagy enhancer carbamazepine alleviates memory deficits and cerebral amyloid-β pathology in a mouse model of Alzheimer's disease. Curr Alzheimer Res, 2013; 10:433–441.
33.
PulsF, GoldschmidtI, BantelH, AgneC, BröckerV, DämmrichM, et al.: Autophagy-enhancing drug carbamazepine diminishes hepatocellular death in fibrinogen storage disease. J Hepatol, 2013; 59:626–630.
34.
MullanLA, MularczykEJ, KungLH, ForouhanM, WraggJM, GoodacreR, et al.: Increased intracellular proteolysis reduces disease severity in an ER stress-associated dwarfism. J Clin Invest, 2017; 127:3861–3865.
35.
MurphyWG, KeltonJG: Methyldopa-induced autoantibodies against red blood cells. Blood Rev, 1988; 2:36–42.
36.
ZhuH, LemosH, BhattB, IslamBN, SinghA, GuravA, et al.: Carbidopa, a drug in use for management of Parkinson disease inhibits T cell activation and autoimmunity. PLoS One, 2017; 12:e0183484.
